Invitris Analysis: $125K Raised
What is Invitris?
Invitris builds a cell-free protein synthesis platform for rapid protein design, expression, and scalable production. Its systems include prokaryotic and mammalian expression workflows, plus microfluidic screening that reaches 1,000 proteins per second. The company positions its platform for biopharmaceuticals, antimicrobial resistance, phage production, industrial biotechnology, and agriculture.
Location
Munich, Germany
Employees
1-10
Founded
2022
Product Features & Capabilities
- human therapeutics, industrial applications, synthetic proteins, phages, tailocins, endolysins, neoantigens, vaccines, antibodies, toxic proteins (nucleases, proteases), prokaryotic cell-free expression systems, eukaryotic cell-free expression systems, applications in human health, agriculture, animal health, food, industrial chemistry
How much Invitris raised
1 - $125K
2023Lead Investor: Y Combinator
Who are the founders of Invitris
PG
Patrick Grossman
CEO & Co-Founder
KV
Kilian Vogele
CTO & Co-Founder
Business Model
Partnerships for product development; revenue from sales of synthetic proteins and services.
Competitors Overview
The main competitors of Invitris in the synthetic protein market include:
-
Thermo Fisher Scientific, Inc.: A leading provider of scientific instruments, reagents, and consumables, Thermo Fisher offers a wide range of products for protein synthesis and cell-free expression technologies. Their extensive portfolio and established market presence provide them with a significant advantage.
-
Takara Bio Inc.: This company specializes in biotechnology and offers various products for molecular biology, including cell-free protein synthesis systems. Takara Bio is known for its innovative solutions and strong focus on research and development.
-
Merck KGaA: A global science and technology company, Merck provides a variety of products and services in the life sciences sector, including cell-free expression systems. Their broad expertise and resources allow them to cater to diverse customer needs.
-
New England Biolabs (NEB): NEB is renowned for its high-quality reagents for DNA research and protein synthesis. Their strong reputation in the scientific community and commitment to innovation give them a competitive edge.
-
Promega Corporation: Promega offers a range of products for protein expression and purification, including cell-free systems. Their focus on user-friendly solutions and customer support enhances their market position.
-
Sutro Biopharma, Inc.: This company focuses on developing protein therapeutics using its proprietary cell-free expression technology. Sutro's unique approach to protein synthesis and therapeutic development sets it apart in the market.
-
Biotechrabbit GmbH: Specializing in high-quality reagents for molecular biology, Biotechrabbit provides solutions for cell-free protein synthesis, emphasizing quality and reliability.
Notable differences and advantages among these competitors include their specific technological innovations, product offerings, market focus, and customer support services, which can influence their competitive positioning in the synthetic protein market.
Market Focus
Invitris primarily focuses on the biotechnology industry, specifically in the development and manufacturing of synthetic proteins for human therapeutics and industrial applications.
Investors
- 10x Founders
- another.vc
- European Innovation Council Fund
- Mergus Ventures
- Phoenix Investment
See something that needs updating? Suggest edits to this profile.